BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 22172840)

  • 21. Late onset of bladder urothelial carcinoma after kidney transplantation for end-stage aristolochic acid nephropathy: a case series with 15-year follow-up.
    Lemy A; Wissing KM; Rorive S; Zlotta A; Roumeguere T; Muniz Martinez MC; Decaestecker C; Salmon I; Abramowicz D; Vanherweghem JL; Nortier J
    Am J Kidney Dis; 2008 Mar; 51(3):471-7. PubMed ID: 18295063
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Linking environmental carcinogen exposure to TP53 mutations in human tumours using the human TP53 knock-in (Hupki) mouse model.
    Kucab JE; Phillips DH; Arlt VM
    FEBS J; 2010 Jun; 277(12):2567-83. PubMed ID: 20553493
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Urothelial carcinoma associated with the use of a Chinese herb (Aristolochia fangchi).
    Nortier JL; Martinez MC; Schmeiser HH; Arlt VM; Bieler CA; Petein M; Depierreux MF; De Pauw L; Abramowicz D; Vereerstraeten P; Vanherweghem JL
    N Engl J Med; 2000 Jun; 342(23):1686-92. PubMed ID: 10841870
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Porocarcinomas harbor recurrent HRAS-activating mutations and tumor suppressor inactivating mutations.
    Harms PW; Hovelson DH; Cani AK; Omata K; Haller MJ; Wang ML; Arps D; Patel RM; Fullen DR; Wang M; Siddiqui J; Andea A; Tomlins SA
    Hum Pathol; 2016 May; 51():25-31. PubMed ID: 27067779
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Role of oncogenic pathways and KRAS/BRAF mutations in the behavior of colon adenocarcinoma in renal transplant patients.
    Revuelta I; Moya-Rull D; García-Herrera A; Rovira J; Ayala de la Peña F; Misiego A; Guzmán F; Oppenheimer F; Albanell J; Campistol JM
    Transplantation; 2012 Mar; 93(5):509-17. PubMed ID: 22245873
    [TBL] [Abstract][Full Text] [Related]  

  • 26. PI3K/AKT pathway activation in bladder carcinogenesis.
    Calderaro J; Rebouissou S; de Koning L; Masmoudi A; Hérault A; Dubois T; Maille P; Soyeux P; Sibony M; de la Taille A; Vordos D; Lebret T; Radvanyi F; Allory Y
    Int J Cancer; 2014 Apr; 134(8):1776-84. PubMed ID: 24122582
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Mutational screening of RET, HRAS, KRAS, NRAS, BRAF, AKT1, and CTNNB1 in medullary thyroid carcinoma.
    Schulten HJ; Al-Maghrabi J; Al-Ghamdi K; Salama S; Al-Muhayawi S; Chaudhary A; Hamour O; Abuzenadah A; Gari M; Al-Qahtani M
    Anticancer Res; 2011 Dec; 31(12):4179-83. PubMed ID: 22199277
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A novel p53 mutant found in iatrogenic urothelial cancers is dysfunctional and can be rescued by a second-site global suppressor mutation.
    Odell AF; Odell LR; Askham JM; Alogheli H; Ponnambalam S; Hollstein M
    J Biol Chem; 2013 Jun; 288(23):16704-16714. PubMed ID: 23612969
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The impact of TP53 and RAS mutations on cerebellar glioblastomas.
    Milinkovic VP; Skender Gazibara MK; Manojlovic Gacic EM; Gazibara TM; Tanic NT
    Exp Mol Pathol; 2014 Oct; 97(2):202-7. PubMed ID: 25036404
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Urologic de novo malignancies after kidney transplantation: a single center experience.
    Karczewski M; Czapiewski W; Karczewski J
    Transplant Proc; 2012 Jun; 44(5):1293-7. PubMed ID: 22664003
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Invasive urothelial carcinoma after exposure to Chinese herbal medicine containing aristolochic acid may occur without severe renal failure.
    Nortier JL; Schmeiser HH; Muniz Martinez MC; Arlt VM; Vervaet C; Garbar CH; Daelemans P; Vanherweghem JL
    Nephrol Dial Transplant; 2003 Feb; 18(2):426-8. PubMed ID: 12543902
    [No Abstract]   [Full Text] [Related]  

  • 32. Cross-generational effects of alcohol dependence in humans on HRAS and TP53 methylation in offspring.
    Hill SY; Rompala G; Homanics GE; Zezza N
    Epigenomics; 2017 Sep; 9(9):1189-1203. PubMed ID: 28799801
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A Phase II Trial of Tipifarnib for Patients with Previously Treated, Metastatic Urothelial Carcinoma Harboring
    Lee HW; Sa JK; Gualberto A; Scholz C; Sung HH; Jeong BC; Choi HY; Kwon GY; Park SH
    Clin Cancer Res; 2020 Oct; 26(19):5113-5119. PubMed ID: 32636318
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Genomic aberrations are rare in urothelial neoplasms of patients 19 years or younger.
    Wild PJ; Giedl J; Stoehr R; Junker K; Boehm S; van Oers JM; Zwarthoff EC; Blaszyk H; Fine SW; Humphrey PA; Dehner LP; Amin MB; Epstein JI; Hartmann A
    J Pathol; 2007 Jan; 211(1):18-25. PubMed ID: 17072825
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Mutation of TP53 and alteration of p14(arf) expression in EGFR- and KRAS-mutated lung adenocarcinomas.
    Cortot AB; Younes M; Martel-Planche G; Guibert B; Isaac S; Souquet PJ; Commo F; Girard P; Fouret P; Brambilla E; Hainaut P; Soria JC
    Clin Lung Cancer; 2014 Mar; 15(2):124-30. PubMed ID: 24169260
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Mutational spectrum of conserved regions of TP53 and PTEN genes in Kangri cancer (of the skin) in the Kashmiri population.
    Hussain I; ul Rehman S; Afroze D; Zahoor L; Abdullah S; Hafiz A; Shah ZA; Iqbal S; Shaffi M; Das BC; Siddiqi MA
    Mutat Res; 2009 May; 676(1-2):5-10. PubMed ID: 19486858
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Analysis of potential risk factors for cancer incidence in patients with aristolochic acid nephropathy from Wenzhou, China.
    Sun M; Zhang J; Zheng C; Liu Y; Lin F; Xu F; Chen C
    Ren Fail; 2015 Mar; 37(2):209-13. PubMed ID: 25540870
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Increased risk of urinary tract cancer in ESRD patients associated with usage of Chinese herbal products suspected of containing aristolochic acid.
    Wang SM; Lai MN; Wei A; Chen YY; Pu YS; Chen PC; Wang JD
    PLoS One; 2014; 9(8):e105218. PubMed ID: 25170766
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A retrospective review of patients with urothelial cancer in 3,370 recipients after renal transplantation: a single-center experience.
    Zhang A; Shang D; Zhang J; Zhang L; Shi R; Fu F; Tian Y
    World J Urol; 2015 May; 33(5):713-7. PubMed ID: 25239501
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [p53 mutation in phenacetin-induced urothelial carcinomas].
    Petersen I; Ohgaki H; Ludeke BI; Kleihues P
    Verh Dtsch Ges Pathol; 1993; 77():252-5. PubMed ID: 7511292
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.